drugset / Trial / NCT03837821
(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer
Phase 0
Active not recruiting
20 enrolled
Weill Medical College of Cornell University
Eli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment
Summary
Single-arm, open-label window-of-opportunity trial of neoadjuvant Abemaciclib in 20 patients, with tumor tissue obtained as standard of care at tumor resection (pre-Abemaciclib) and cystectomy (post-Abemaciclib)
Timeline
- Start
- 2019-02-05
- Primary completion
- 2024-07-02
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 200 mg | Oral |